These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15888768)

  • 1. ESMO recommendations for the application of hematopoietic growth factors.
    Greil R; Jost LM;
    Ann Oncol; 2005; 16 Suppl 1():i80-2. PubMed ID: 15888768
    [No Abstract]   [Full Text] [Related]  

  • 2. Myeloid growth factors.
    Crawford J; Armitage J; Balducci L; Bennett C; Blayney DW; Cataland SR; Dale DC; Demetri GD; Erba HP; Foran J; Freifeld AG; Goemann M; Heaney ML; Htoy S; Hudock S; Kloth DD; Kuter DJ; Lyman GH; Michaud LB; Miyata SC; Tallman MS; Vadhan-Raj S; Westervelt P; Wong MK;
    J Natl Compr Canc Netw; 2009 Jan; 7(1):64-83. PubMed ID: 19176207
    [No Abstract]   [Full Text] [Related]  

  • 3. Hematopoietic growth factors: ESMO recommendations for the application.
    ; Greil R; Psenak O
    Ann Oncol; 2007 Apr; 18 Suppl 2():ii89-91. PubMed ID: 17491063
    [No Abstract]   [Full Text] [Related]  

  • 4. Pegfilgrastim lowers side-effects of chemotherapy.
    Sharma DC
    Lancet Oncol; 2004 Aug; 5(8):461. PubMed ID: 15309779
    [No Abstract]   [Full Text] [Related]  

  • 5. Myeloid growth factors clinical practice guidelines in oncology.
    Crawford J; Althaus B; Armitage J; Blayney DW; Cataland S; Dale DC; Demetri GD; Foran J; Heaney ML; Htoy S; Kloth DD; Lyman GH; Michaud L; Motl S; Vadhan-Raj S; Wong MK;
    J Natl Compr Canc Netw; 2005 Jul; 3(4):540-55. PubMed ID: 16038645
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic growth factors: ESMO recommendations for the applications.
    Greil R; Psenak O; Roila F;
    Ann Oncol; 2008 May; 19 Suppl 2():ii116-8. PubMed ID: 18456747
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of filgrastim for stem cell mobilisation and transplantation in high-dose cancer chemotherapy.
    Anderlini P; Champlin R
    Drugs; 2002; 62 Suppl 1():79-88. PubMed ID: 12479596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colony-stimulating factors for febrile neutropenia during cancer therapy.
    Bennett CL; Djulbegovic B; Norris LB; Armitage JO
    N Engl J Med; 2013 Mar; 368(12):1131-9. PubMed ID: 23514290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.
    Strassels SA; Dickson M; Norris LB; Bennett CL
    J Natl Cancer Inst; 2013 Aug; 105(15):1072-3. PubMed ID: 23873406
    [No Abstract]   [Full Text] [Related]  

  • 11. New treatment options for managing chemotherapy-induced neutropenia.
    Valley AW
    Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S11-7. PubMed ID: 12166032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
    Crawford J
    Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
    Crawford J; Caserta C; Roila F;
    Ann Oncol; 2010 May; 21 Suppl 5():v248-51. PubMed ID: 20555091
    [No Abstract]   [Full Text] [Related]  

  • 14. Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia.
    Petros WP
    Pharmacotherapy; 2003 Aug; 23(8 Pt 2):1S-2S; quiz 20S-23S. PubMed ID: 12921215
    [No Abstract]   [Full Text] [Related]  

  • 15. An analysis of current neutropenia therapies, including pegfilgrastim.
    Gabrilove JL
    Clin Cornerstone; 2006; 8 Suppl 5():S19-28. PubMed ID: 17379160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic growth factors for chemotherapy-induced neutropenia.
    Yalçin S
    Cancer Invest; 1999; 17(7):555-6. PubMed ID: 10518202
    [No Abstract]   [Full Text] [Related]  

  • 18. Feasibility and kinetics of CD34
    Takhar H; Mislang AR; Singhal N; Brown MP
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):79-86. PubMed ID: 27649817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G; Lalla A; Barron R; Dubois RW
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.